ABBV
AbbVie Inc
NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$203.89
+3.14% today
Updated 2026-04-29
Market cap
$351.47B
P/E ratio
84.20
P/S ratio
5.75x
EPS (TTM)
$2.36
Dividend yield
3.31%
52W range
$171 – $239
Volume
6.9M
WallStSmart proprietary scores
63
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C5.0
Quality
C+8.0
Profitability
A4.7
Valuation
C5/9
Piotroski F-Score
Moderate
0.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$249.27
+22.26%
12-Month target
$16.05
-92.13%
Intrinsic (DCF)
$163.42
Margin of safety
-24.92%
8 Strong Buy14 Buy9 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 62.30% — strong efficiency
+ Free cash flow $4.89B — positive
+ Debt/equity -21.06x — low leverage
Risks
- Altman Z 0.40 — distress zone
- 24.92% above intrinsic value
- P/E 84.20x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $58.05B | $54.32B | $56.33B | $61.16B | $61.16B | $68.4B |
| Net income | $11.84B | $4.86B | $4.28B | $4.23B | $1.82B | — |
| EPS | — | — | — | — | $2.36 | $14.83 |
| Free cash flow | $24.25B | $22.06B | $17.83B | $17.82B | $4.89B | — |
| Profit margin | 20.39% | 8.95% | 7.59% | 6.91% | 6.91% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | RAPP, EDWARD J | Buy | 155 | $217.49 |
| 2026-03-31 | QUAGGIN, SUSAN E | Buy | 71 | $217.49 |
| 2026-03-31 | ALPERN, ROBERT J | Buy | 35 | $217.49 |
Peer comparison
Smart narrative
AbbVie Inc trades at $203.89. representing a P/E of 84.20x trailing earnings. Our Smart Value Score of 63/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.40, it sits in the distress. TTM revenue stands at $61.16B. with profit margins at 6.91%. Our DCF model estimates intrinsic value at $163.42.
Frequently asked questions
What is AbbVie Inc's stock price?
AbbVie Inc (ABBV) trades at $203.89.
Is AbbVie Inc overvalued?
Smart Value Score 63/100 (Grade C+, Hold). DCF value $163.42.
What is the price target of AbbVie Inc (ABBV)?
The analyst target price is $249.27, representing +22.3% upside from the current price of $203.89.
What is the intrinsic value of AbbVie Inc (ABBV)?
Based on our DCF model, intrinsic value is $163.42, a -24.9% margin of safety versus $203.89.
What is the future stock price of ABBV by 2030?
Our research-backed model estimates AbbVie Inc could reach $218.58 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is AbbVie Inc's revenue?
TTM revenue is $61.16B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
0.40 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio5.75x
ROE62.30%
Beta0.36
50D MA$217.10
200D MA$217.63
Shares out1.77B
Float1.77B
Short ratio—
Avg volume6.9M
Performance
1 week+1.46%
1 month-6.25%
3 months-7.50%
YTD-10.77%
1 year—
3 years—
5 years—